<DOC>
	<DOCNO>NCT00392379</DOCNO>
	<brief_summary>This study randomize , blind , placebo-controlled two-group clinical trial . The independent variable treatment assignment ( active 4-mg nicotine lozenge vs. match placebo lozenge ) , dependent variable tobacco ST abstinence 3 6 month . ST user randomly assign either 4-mg active nicotine lozenge match placebo .</brief_summary>
	<brief_title>Nicotine Lozenges Treatment Smokeless Tobacco Addiction</brief_title>
	<detailed_description>Smokeless tobacco ( ST ) user randomly assign either 4-mg active nicotine lozenge match placebo . Both group receive behavioral intervention . The two site clinical trial Mayo Clinic Rochester , Minnesota ( central coordinate site ) Oregon Research Institute ( ORI ) Eugene , OR . A total 270 ST user recruit clinical trail . All subject randomize 4 mg Nicotine Lozenges ( take ad lib ) match placebo . They study medication 12 week follow 6 month study enrollment</detailed_description>
	<mesh_term>Nicotine</mesh_term>
	<mesh_term>Lobeline</mesh_term>
	<criteria>least 18 year age ; report smokeless tobacco ( ST ) primary tobacco use ; use ST daily past 6 month ; general good health ( determined medical history screen physical examination ) ; provide , understand , sign informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Tobacco use disorder</keyword>
	<keyword>Tobacco cessation</keyword>
</DOC>